135 related articles for article (PubMed ID: 30185536)
1. DNA Methylation of
Guo Y; Zhang R; Shen S; Wei Y; Salama SM; Fleischer T; Bjaanæs MM; Karlsson A; Planck M; Su L; Zhu Z; Staaf J; Helland Å; Esteller M; Christiani DC
Cancer Epidemiol Biomarkers Prev; 2018 Dec; 27(12):1527-1535. PubMed ID: 30185536
[TBL] [Abstract][Full Text] [Related]
2. A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
Sandoval J; Mendez-Gonzalez J; Nadal E; Chen G; Carmona FJ; Sayols S; Moran S; Heyn H; Vizoso M; Gomez A; Sanchez-Cespedes M; Assenov Y; Müller F; Bock C; Taron M; Mora J; Muscarella LA; Liloglou T; Davies M; Pollan M; Pajares MJ; Torre W; Montuenga LM; Brambilla E; Field JK; Roz L; Lo Iacono M; Scagliotti GV; Rosell R; Beer DG; Esteller M
J Clin Oncol; 2013 Nov; 31(32):4140-7. PubMed ID: 24081945
[TBL] [Abstract][Full Text] [Related]
3. LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy.
Luo L; Fu S; Du W; He LN; Zhang X; Wang Y; Zhou Y; Hong S
Front Immunol; 2023; 14():959868. PubMed ID: 36798137
[TBL] [Abstract][Full Text] [Related]
4. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
[TBL] [Abstract][Full Text] [Related]
5. A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer.
Shen S; Zhang R; Guo Y; Loehrer E; Wei Y; Zhu Y; Yuan Q; Moran S; Fleischer T; Bjaanaes MM; Karlsson A; Planck M; Staaf J; Helland Å; Esteller M; Su L; Chen F; Christiani DC
Mol Oncol; 2018 Jun; 12(6):913-924. PubMed ID: 29656435
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modifications in
Wei Y; Liang J; Zhang R; Guo Y; Shen S; Su L; Lin X; Moran S; Helland Å; Bjaanæs MM; Karlsson A; Planck M; Esteller M; Fleischer T; Staaf J; Zhao Y; Chen F; Christiani DC
Clin Epigenetics; 2018; 10():41. PubMed ID: 29619118
[TBL] [Abstract][Full Text] [Related]
7. Methylation markers of early-stage non-small cell lung cancer.
Lokk K; Vooder T; Kolde R; Välk K; Võsa U; Roosipuu R; Milani L; Fischer K; Koltsina M; Urgard E; Annilo T; Metspalu A; Tõnisson N
PLoS One; 2012; 7(6):e39813. PubMed ID: 22768131
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers.
Yoshino M; Suzuki M; Tian L; Moriya Y; Hoshino H; Okamoto T; Yoshida S; Shibuya K; Yoshino I
Int J Oncol; 2009 Nov; 35(5):1201-9. PubMed ID: 19787276
[TBL] [Abstract][Full Text] [Related]
9. EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC.
Zhang R; Lai L; He J; Chen C; You D; Duan W; Dong X; Zhu Y; Lin L; Shen S; Guo Y; Su L; Shafer A; Moran S; Fleischer T; Bjaanæs MM; Karlsson A; Planck M; Staaf J; Helland Å; Esteller M; Wei Y; Chen F; Christiani DC
Epigenetics; 2019 Feb; 14(2):118-129. PubMed ID: 30665327
[TBL] [Abstract][Full Text] [Related]
10. Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects.
Zhang R; Chen C; Dong X; Shen S; Lai L; He J; You D; Lin L; Zhu Y; Huang H; Chen J; Wei L; Chen X; Li Y; Guo Y; Duan W; Liu L; Su L; Shafer A; Fleischer T; Moksnes Bjaanæs M; Karlsson A; Planck M; Wang R; Staaf J; Helland Å; Esteller M; Wei Y; Chen F; Christiani DC
Chest; 2020 Aug; 158(2):808-819. PubMed ID: 32113923
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
12. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
[TBL] [Abstract][Full Text] [Related]
13. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Tian FM; Zhong CY; Wang XN; Meng Y
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
[TBL] [Abstract][Full Text] [Related]
14. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
Dötsch MM; Kloten V; Schlensog M; Heide T; Braunschweig T; Veeck J; Petersen I; Knüchel R; Dahl E
Epigenetics; 2015; 10(10):903-12. PubMed ID: 26252352
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
[TBL] [Abstract][Full Text] [Related]
16. Epigenome-wide gene-age interaction analysis reveals reversed effects of
Chen C; Wei Y; Wei L; Chen J; Chen X; Dong X; He J; Lin L; Zhu Y; Huang H; You D; Lai L; Shen S; Duan W; Su L; Shafer A; Fleischer T; Bjaanæs MM; Karlsson A; Planck M; Wang R; Staaf J; Helland Å; Esteller M; Zhang R; Chen F; Christiani DC
Aging (Albany NY); 2020 Jun; 12(11):10642-10662. PubMed ID: 32511103
[TBL] [Abstract][Full Text] [Related]
17. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
Ooki A; Maleki Z; Tsay JJ; Goparaju C; Brait M; Turaga N; Nam HS; Rom WN; Pass HI; Sidransky D; Guerrero-Preston R; Hoque MO
Clin Cancer Res; 2017 Nov; 23(22):7141-7152. PubMed ID: 28855354
[No Abstract] [Full Text] [Related]
18. Clinical significance of long non-coding RNA HOTTIP in early-stage non-small-cell lung cancer.
Navarro A; Moises J; Santasusagna S; Marrades RM; Viñolas N; Castellano JJ; Canals J; Muñoz C; Ramírez J; Molins L; Monzo M
BMC Pulm Med; 2019 Feb; 19(1):55. PubMed ID: 30819158
[TBL] [Abstract][Full Text] [Related]
19. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
[TBL] [Abstract][Full Text] [Related]
20. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
